Literature DB >> 20668832

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

P L Drury1, R Ting, D Zannino, C Ehnholm, J Flack, M Whiting, R Fassett, J-C Ansquer, P Dixon, T M E Davis, C Pardy, P Colman, A Keech.   

Abstract

AIMS/HYPOTHESIS: We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
METHODS: Baseline and year 2 renal status were examined in relation to clinical and biochemical characteristics. Outcomes included total cardiovascular disease (CVD), cardiac and non-cardiac death over 5 years.
RESULTS: Lower estimated GFR (eGFR) vs eGFR ≥90 ml min⁻¹ 1.73 m⁻² was a risk factor for total CVD events: (HR [95% CI] 1.14 [1.01-1.29] for eGFR 60-89 ml min⁻¹ 1.73 m⁻²; 1.59 [1.28-1.98] for eGFR 30-59 ml min⁻¹ 1.73 m⁻²; p < 0.001; adjusted for other characteristics). Albuminuria increased CVD risk, with microalbuminuria and macroalbuminuria increasing total CVD (HR 1.25 [1.01-1.54] and 1.19 [0.76-1.85], respectively; p = 0.001 for trend) when eGFR ≥90 ml min⁻¹ 1.73 m⁻². CVD risk was further modified by renal status changes over the first 2 years. In multivariable analysis, 77% of the effect of eGFR and 81% of the effect of albumin:creatinine ratio were accounted for by other variables, principally low HDL-cholesterol and elevated blood pressure. CONCLUSIONS/
INTERPRETATION: Reduced eGFR and albuminuria are independent risk factors for cardiovascular events and mortality rates in a low-risk population of mainly European ancestry. While their independent contributions to CVD risk appear small when other risk factors are considered, they remain excellent surrogate markers in clinical practice because they capture risk related to a number of other characteristics. Therefore, both should be considered when assessing prognosis and treatment strategies in patients with diabetes, and both should be included in risk models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668832     DOI: 10.1007/s00125-010-1854-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  47 in total

1.  Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

Authors:  Ravi Retnakaran; Carole A Cull; Kerensa I Thorne; Amanda I Adler; Rury R Holman
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

2.  Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients.

Authors:  Wing Yee So; Alice P S Kong; Ronald C W Ma; Risa Ozaki; Cheuk Chun Szeto; Norman N Chan; Vanessa Ng; Chung Shun Ho; Christopher W K Lam; Chun Chung Chow; Clive S Cockram; Juliana C N Chan; Peter C Y Tong
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

Review 3.  Endothelial dysfunction and pathogenesis of diabetic angiopathy.

Authors:  C D Stehouwer; J Lambert; A J Donker; V W van Hinsbergh
Journal:  Cardiovasc Res       Date:  1997-04       Impact factor: 10.787

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 5.  Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.

Authors:  N D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2006-02

6.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

Authors: 
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

7.  Relation between kidney function, proteinuria, and adverse outcomes.

Authors:  Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli
Journal:  JAMA       Date:  2010-02-03       Impact factor: 56.272

8.  Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study.

Authors:  Ronald M A Henry; Piet J Kostense; Griët Bos; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Lex M Bouter; Coen D A Stehouwer
Journal:  Kidney Int       Date:  2002-10       Impact factor: 10.612

9.  Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.

Authors:  Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova; John Robson; Rubin Minhas; Aziz Sheikh; Peter Brindle
Journal:  BMJ       Date:  2008-06-23

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  62 in total

1.  Chronic kidney disease: Albuminuria or CKD stage as best marker of CVD in diabetes?

Authors:  Judith Blaine; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2012-05-29       Impact factor: 28.314

2.  Renal function and cardiovascular events: relevance of eGFR and albuminuria in patients with diabetes.

Authors:  C Delles; A G Jardine
Journal:  Diabetologia       Date:  2010-10-13       Impact factor: 10.122

Review 3.  Clinical impact of albuminuria in diabetic nephropathy.

Authors:  Takashi Wada; Miho Shimizu; Tadashi Toyama; Akinori Hara; Shuichi Kaneko; Kengo Furuichi
Journal:  Clin Exp Nephrol       Date:  2011-08-10       Impact factor: 2.801

4.  Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.

Authors:  Kouichi Tamura; Hiromichi Wakui; Kengo Azushima; Kazushi Uneda; Satoshi Umemura
Journal:  Hypertens Res       Date:  2016-01-28       Impact factor: 3.872

5.  Trends in estimated kidney function: the FINRISK surveys.

Authors:  Auni Juutilainen; Helena Kastarinen; Riitta Antikainen; Markku Peltonen; Veikko Salomaa; Jaakko Tuomilehto; Pekka Jousilahti; Jouko Sundvall; Tiina Laatikainen; Mika Kastarinen
Journal:  Eur J Epidemiol       Date:  2012-04       Impact factor: 8.082

Review 6.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Dragana Lovre; Sulay Shah; Aanu Sihota; Vivian A Fonseca
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12-18       Impact factor: 4.741

7.  Do fibrates truly preserve kidney function?

Authors:  Suneel M Udani; George L Bakris
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

Review 8.  Fenofibrate: a review of its use in dyslipidaemia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

9.  Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.

Authors:  Giuseppe Penno; Anna Solini; Emanuela Orsi; Enzo Bonora; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Olga Lamacchia; Marco Scardapane; Antonio Nicolucci; Giuseppe Pugliese
Journal:  Diabetologia       Date:  2018-07-21       Impact factor: 10.122

10.  Diabetes: Assessing renal risk in patients with type 2 diabetes.

Authors:  Merlin C Thomas; Per-Henrik Groop
Journal:  Nat Rev Nephrol       Date:  2013-09-17       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.